The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2016

Filed:

Jul. 21, 2014
Applicant:

Bioarctic Neuroscience Ab, Stockholm, SE;

Inventors:

Lars Lannfelt, Stockholm, SE;

Joakim Bergström, Uppsala, SE;

Martin Ingelsson, Uppsala, SE;

Pär Gellerfors, Lindingö, SE;

Assignee:

BioArctic Neuroscience AB, Stockholm, SE;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 38/1709 (2013.01); G01N 33/6896 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4709 (2013.01); Y10S 530/839 (2013.01);
Abstract

Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).


Find Patent Forward Citations

Loading…